IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients

Summary

This is a monocenter, single-arm, prospective phase Ib trial, designed to evaluate the safety, clinical toxicity and in vivo immunological effects of a patient-individualized peptide vaccination added to standard of care checkpoint blockade (nivolumab) in adult patients with metastatic/advanced renal cell carcinoma who experienced at least stable disease after four cycles of standard of care immune therapy (ipilimumab/nivolumab).

Timeline

Start

2022-10-17

Primary completion

2024-09-15

Completion

2024-09-15

Outcome

Outcome not reported

Stopped (Enrollment): “Premature discontinuation due to üoor participant recruitment”

Drugs

Indications